Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
Article in Cost Effectiveness and Resource Allocation (May 2018)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
Article in International Journal of Chronic Obstructive Pulmonary Disease (March 2017)
Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations
Article in PharmacoEconomics (September 2016)